In an effort to learn more about whether liraglutide could improve beta-cell function in patients with type 2 diabetes, researchers conducted a double blind, randomized, placebo-controlled trial in 51 patients. They administered liraglutide or placebo and evaluated patients using the Insulin Sensitivity-Secretion Index-2 (ISSI-2).
Results revealed that liraglutide did have an impact on beta-cell function in this patient population.
READ FULL ARTICLE
From Diabetesjournals